Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma.
Source
Department of Physiology, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain. gorka.larrinaga@ehu.es
Abstract
OBJECTIVE:
To analyze the mRNA and protein expression of cannabinoid receptors CB1 and CB2 in chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO).
DESIGN AND METHODS:
Fresh and formalin-fixed tissue samples of ChRCC and RO were analyzed by using real-time quantitative RT-PCR and immunohistochemical techniques (n=40).
RESULTS:
Quantitative RT-PCR analysis showed that CB1 mRNA was underexpressed by 12-fold in ChRCC and had a variable expression in RO. CB1 protein showed intense positive immunostaining in both neoplasms. Both CB2 mRNA and protein were not expressed in tumor and non tumor renal tissue.
CONCLUSION:
This distinct immunoprofile may eventually be used as an additional tool with practical interest in the differential diagnosis of renal tumors.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
- PMID:
- 23318578
- [PubMed – in process]
Publication Types
Publication Types
LinkOut – more resources
Full Text Sources
Other Literature Sources
Figures and tables from this article:
- Fig. 1. mRNA expression of the cannabinoid CB1 receptor in kidney tumor (T) and surrounding normal tissue (N) from two different patients. Agarose gel showing the presence of a single transcript, corresponding to the expected product size encoding the CB1 receptor (131 bp, CNR1). The mRNA encoding the 110 bp product expected for the cannabinoid CB2 receptor (CNR2) was undetectable. The expression of SHDA, one of the genes used as internal control, is also shown. M, molecular size standards; +, positive control showing the expression of all genes in a pool of cDNAs from 20 different human tissues; and −, negative control with no RNA in the reverse transcriptase reaction.
- Fig. 2. mRNA levels of CNR1 measured in tumor and nontumor tissues (normal) from ChRCC (n = 8) and RO (n = 6) patients. qRT-PCR data for each analyzed sample are recorded as relative units (× 10− 5). *Statistically significant (p < 0.05).
- Fig. 3. Microscopic detail of representative areas of chromophobe renal cell carcinoma, renal oncocytoma and clear cell renal cell carcinoma showing non neoplastic collecting ducts (A), chromophobe renal cell carcinoma (C), renal oncocytoma (E) and clear cell renal cell carcinoma (G) (× 400). CB1 immunostaining showing selective staining of intercalated cells (B) and diffuse and intense immunostaining of chromophobe renal cell carcinoma (D) and renal oncocytoma (F), and negative staining in clear cell renal cell carcinoma (H) (original magnification, × 400).
- Table 1. Primer sequences for CNR1, CNR2, TBP, PPIA, ACTB and SDHA.
- View Within Article
- Table 2. Semi-quantitative evaluation of renal tissues. Immunostaining intensities: (−) negative, (+) mild, (++) moderate and (+++) intense.
- View Within Article
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
